Nexium Buyers Point To Dow Ruling To Support Class Cert.
Plaintiffs fighting AstraZeneca PLC and other drug producers' attempt to nix their class certification in a suit over alleged pay-for-delay deals regarding the acid reflux medication Nexium sought to bolster their...To view the full article, register now.
Already a subscriber? Click here to view full article